Search clinical trials for: PF-06651600 or Placebo

Total 1172 results

Pfizer

Completed

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Spain, Israel, Korea, Republic of, Russian Federation, Turkey, Czechia, Hungary, Italy, Poland, Bulgaria, Denmark, Germany, Serbia, Austria, Slovakia, Ukraine, Georgia, Romania
Pfizer

Completed

Safety and Pharmacokinetic Study of PF-06651600 in Healthy Volunteers

Healthy

Belgium
Pfizer

Completed

PF-06651600 for the Treatment of Alopecia Areata (ALLEGRO-2b/3)

Alopecia Areata

China, United States, Spain, Korea, Republic of, Taiwan, Canada, Australia, Germany, Czechia, Poland, Hungary, Japan, United Kingdom, Argentina, Chile, Colombia, Mexico, Russian Federation
Pfizer

Completed

Safety and Pharmacokinetic Study of PF-06651600 in Japanese Healthy Volunteers

Healthy

Belgium
Pfizer

Completed

Study to Characterize Absorption, Distribution, Metabolism and Excretion of 14C PF-06651600 and to Evaluate the Absolute Oral Bioavailability and Fraction Absorbed of PF-06651600. (B7981011)

Healthy Volunteers

Netherlands
Pfizer

Completed

A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTS

Healthy

United States
Pfizer

Completed

Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules.

Healthy Participants

United States
Pfizer

Terminated

A Renal Impairment Study for PF-06651600

Renal Impairment

United States
Pfizer

Completed

Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease

Crohn's Disease

United States, Spain, Lebanon, Australia, Russian Federation, Korea, Republic of, Tunisia, Italy, Poland, Belgium, Austria, Germany, Saudi Arabia, Czechia, Hungary, Switzerland, Turkey, Slovakia, Ukraine, Georgia, Bosnia and Herzegovina and more
Pfizer

Completed

PHARMACOKINETIC CHARACTERIZATION OF PF-06651600 IN CHINESE ADULT PARTICIPANTS

Healthy Participants

China
Emma Guttman
Pfizer

Recruiting

Ritlecitinib for Cicatricial Alopecia

Cicatricial Alopecia

United States
Pfizer

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers

Hepatic Impairment | Healthy Participants

United States
Pfizer

Completed

Bioavailability Study of PF-06651600 Formulations in Healthy Participants

Healthy Volunteers

Belgium
Pfizer

Terminated

A Single Dose Study Of PF-06291874 In Healthy Adult Subjects

Healthy

United States
Pfizer

Completed

A Target Occupancy Study With Ritlecitinib.

Healthy

United States
Pfizer

Completed

Bioavailability Study Of PF-06651600 In Healthy Subjects

Healthy

Belgium
Pfizer

Active, not recruiting

PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA (Allegro2a)

Alopecia Areata

United States, Australia, Canada, Poland
Pfizer

Completed

Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata

Alopecia Areata

United States, Canada, Australia
Pfizer

Not yet recruiting

A Study to Learn About How Different Forms of the Study Medicine Called Ritlecitinib Pass the Intestines of Healthy Male Adults When Taken With or Without Food

Healthy Volunteers
Pfizer

Completed

A Study to Learn About Three Forms of The Study Medicine (Ritlecitinib) in Healthy Adults

Healthy Volunteers

Belgium
Pfizer

Completed

Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate

Rheumatoid Arthritis

United States, Poland, Serbia, Slovakia, Czechia, Georgia, Germany, Bulgaria, Hungary
Pfizer

Completed

A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis

Psoriasis

Canada, United States, Japan, Poland
Pfizer

Completed

A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants

Healthy Volunteers | Pharmacokinetics | Adult

Belgium
Pfizer

Completed

A Single Dose Study Of PF-05161704 In Healthy Volunteers

Diabetes Mellitus, Type 2

United States
Pfizer

Withdrawn

A Study Of Gastrointestinal Tolerability Of PF05212389 In Obese Subjects

Obesity
Pfizer

Completed

A Study Of PF-05175157 In Healthy Volunteers

Diabetes Mellitus, Type 2

United States
Pfizer

Terminated

A Multiple Dose Study Of PF-05161704 In Healthy Volunteers

Diabetes Mellitus, Type 2

United States
Pfizer

Completed

Group Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of PF-04531083 In Healthy Subjects

Healthy Volunteers

Belgium
Pfizer

Completed

A Study of PF-05175157 in Healthy Volunteers and Type 2 Diabetic Patients

Diabetes Mellitus, Type 2

United States
Pfizer

Completed

A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects

Active Non-segmental Vitiligo

Spain, United States, Korea, Republic of, Taiwan, Canada, Australia, Germany, Japan, Belgium, Italy
Pfizer

Not yet recruiting

A Study to Learn About the Study Medicine Called PF-07054894 in People of Japanese Origin

Healthy

Belgium
Pfizer

Terminated

A Single Oral Dose Study Of PF-06409577 In Healthy Adult Subjects

Healthy

Belgium
Pfizer

Terminated

A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients

Diabetes Mellitus, Type 2

United States
Pfizer

Completed

A Study Of PF-04620110 As A Modified-Release Formulation In Healthy Overweight Or Obese Subjects

Healthy

Belgium
Pfizer

Completed

A Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-03882845 In Healthy Volunteers

Healthy Volunteers

United States
Pfizer

Completed

PF-06651600 Taste Study.

Healthy Participants

Belgium
Pfizer

Completed

Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide

Healthy Volunteers

United States
Pfizer

Completed

STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS

Healthy Participants

United States, Belgium
Pfizer

Completed

A Single Dose Study Of PF-06678552 In Healthy Subjects

Healthy

Belgium
Pfizer

Completed

A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Oral Doses Of PF-06273340

PAIN

Belgium
Pfizer

Completed

A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants

Dermatitis Atopic

United States
Pfizer

Terminated

A Study To Investigate Safety, Tolerability, And Pharmacokinetics Of PF-00868554 In Japanese Healthy Adult Volunteers

Healthy Volunteers

United States
Pfizer

Completed

TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE

Rheumatoid Arthritis

Czechia, Hungary, Spain, Poland, Canada, Bulgaria, Chile, Georgia, Slovakia, Ukraine
Pfizer

Completed

Study to Evaluate the Safety, Local and Systemic Tolerability, and Pharmacokinetics of Multiple-Dose Topical Administration of PF-07038124 in Japanese Healthy Participants

Healthy

Japan
Pfizer
Pfizer

Recruiting

A Phase 2/3 Study in Adult and Pediatric Participants With SCD

Sickle Cell Disease

United States, Nigeria, Kenya, Lebanon
Pfizer

Terminated

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

Prostatic Neoplasms

United States
Pfizer

Recruiting

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada
Pfizer

Withdrawn

A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects (A7881006)

Respiratory Tract Diseases | Bronchial Diseases | Lung Diseases, Obstructive | Asthma, Bronchial
Pfizer

Completed

A First In Human Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Single Oral Doses Of PF-06372865

Healthy

Netherlands
Pfizer

Completed

Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) (MIRNA)

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis With Liver Fibrosis

Hong Kong, United States, Taiwan, Puerto Rico, China, Canada, Korea, Republic of, Bulgaria, Japan, India, Poland, Slovakia

3

Subscribe